ArticleDiabetes therapy : research, treatment and education of diabetes and related disorders2021

Cost-Utility Analysis of Dapagliflozin as an Add-On to Standard Treatment for Patients with Type 2 Diabetes and High Risk of Cardiovascular Disease in Thailand.

Chaicharn Deerochanawong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.